Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Dongbao Pharma Acquires Two Diabetes Treatments in $135 Million Deal

publication date: May 15, 2018

Tonghua Dongbao Pharma acquired China rights to two diabetes treatments from Adocia of Lyon, France in an agreement worth up to $135 million. Dongbao will have rights to BioChaperone® Combo, a fixed-ratio insulin glargine and insulin lispro combination, plus BioChaperone® Lispro, an ultra-rapid insulin. Adocia's BioChaperone platform uses polymers, oligomers and small organic compounds to protect proteins from degradation. Dongbao already has a portfolio of diabetes treatments. More details....

Stock Symbols: (SHA: 600867) (Paris: ADOC)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China